A JDRF-funded, world-first clinical trial has shown that a commonly prescribed rheumatoid arthritis drug (baricitinib) can preserve the body’s own insulin production and suppress the progression of type 1 diabetes (T1D) in those newly diagnosed with the condition. This comes after three decades of research out of the St Vincent’s Institute (SVI) in Melbourne, […]
JDRF has just funded a new Australian islet transplantation research project with the potential to revert type 1 diabetes. The benefits of islet transplantation Pancreatic islet transplantation is a life-saving and life-changing treatment currently available for people with type 1 diabetes (T1D) who are unaware of their dangerously low blood glucose levels (known as ‘severe […]
JDRF has funded a new Australian research project which may allow those with type 1 diabetes (T1D) to regenerate lost pancreatic cells. During T1D development, the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. This leads to the loss and destruction of beta cells, meaning that people with T1D are no longer […]
A new study suggests that giving antivirals shortly after a type 1 diabetes (T1D) diagnosis may preserve the body’s ability to produce insulin. Recent results from a clinical trial published in the prestigious Nature journal have suggested that administering the antivirals pleconaril and ribavirin can preserve beta cell function in children and teenagers recently diagnosed […]
This World Diabetes Day, on Tuesday 14th November, students from kindergarten and year 4 at Inaburra School in Sydney’s south participated in screening to detect type 1 diabetes (T1D). This is part of the JDRF-funded Australian Type 1 Diabetes National Screening Pilot, a research project looking to identify early-stage T1D in childhood. It was the first […]
Research findings have just been released for the PROTECT clinical trial which tested whether the disease-modifying therapy Teplizumab is able to delay type 1 diabetes (T1D) progression in those newly diagnosed. What is Teplizumab? Teplizumab is a therapy which has been shown to delay the progression from an early stage of T1D (Stage 2) to […]
JDRF Australia’s Career Support and Travel Grants for domestic and international travel are designed to support the next generation of type 1 diabetes (T1D) researchers. They allow early to mid-career researchers and allied health professionals to gain new skills, exchange knowledge, and establish connections and collaborations. We recently spoke to David de George, PhD student […]
Are you passionate about creating a world where research breakthroughs in type 1 diabetes (T1D) are rapidly turned into tangible treatments; a world where the most promising discoveries don’t just remain in labs but make their way swiftly to those who need them the most? Do you have a pioneering research project, innovative idea, or […]
In people newly diagnosed with type 1 diabetes (T1D) there is often a ‘honeymoon’ phase where some pancreatic beta cells are still able to produce insulin. Committed to improving the lives of those with T1D, JDRF has invested in several clinical studies under the Australasian Type 1 Diabetes Immunotherapy Collaborative (ATIC), investigating whether we can […]
Bringing researchers together to celebrate past and future type 1 diabetes breakthroughs On the 24th and 25th July 2023, JDRF Australia was delighted to host a research symposium: T1Decade of Research Progress – Past & Future to commemorate over a decade of achievements of the Type 1 Diabetes Clinical Research Network (T1DCRN). The T1DCRN is […]
JDRF Australia is delighted to announce the recipients of our 2023 PhD top-up scholarships: Rachel Hicks from Western Sydney University and Amanda Purcell from The Kolling Institute. The top-up scholarship is designed to support and encourage PhD students pursuing research in the field of type 1 diabetes (T1D) in line with JDRF’s mission – to […]
JDRF Australia is excited to announce our partnership with Cicada Innovations, leaders in deep tech incubation to accelerate scientific progress and bridge translation gaps. Our partnership will accelerate type 1 diabetes (T1D) research translation and commercialisation through providing resources, mentorship, funding, and networking opportunities. Our goal is to bring scientific discoveries into real-world solutions for […]
A new study has shown drug Verapamil, regularly used to treat blood pressure, can slow type 1 diabetes progression in newly diagnosed children and teens. As researchers work to cure type 1 diabetes (T1D), the ultimate goal is to prevent the destruction of beta cells that produce insulin. A new JDRF-funded clinical trial reveals a […]
MEDIA RELEASE Australia leading type 1 diabetes research with $12M invested to progress landmark study The funding will support the extension of ENDIA, a world-first study seeking to understand the role of environmental triggers from as early as pregnancy for the onset of type 1 diabetes (T1D). 4 April 2023: JDRF Australia and funding partner […]
“The ultimate goal is to help develop vaccines to prevent T1D, as well as antiviral therapeutics to potentially treat people already diagnosed with T1D” Dr Kim’s work aims to uncover the link between viruses and type 1 diabetes (T1D). As one of the lead investigators of ENDIA, Dr Kim is looking at whether early infection […]
We sat down with Dr Aveni Haynes to hear from a woman in STEM who inspires in the world of type 1 diabetes (T1D). What drew you to a career in T1D research? “While training to become a doctor, I was fascinated by the complexity and ingenuity of the human body and to date I […]
The T1D Index is a first-of-its-kind data simulation tool that measures the human and public health impact of the T1D crisis in every country across the globe.
Eye damage in people living with type 1 diabetes (T1D) People living with T1D are 25 times more likely to develop vision loss than those living without the condition. The strict control of blood glucose levels necessary for the prevention of diabetic eye disease (retinopathy) is often difficult to achieve. Further, even if blood glucose […]